title: [The clinical efficacy and safety study of Esculin and Digitalis glycosides Eye Drops in treating ametropic asthenopia].
abstract: OBJECTIVE
  To study the clinical efficacy and safety of the Esculin and Digitalis glycosides Eye Drops used in the patients of ametropic asthenopia.
  
  
  METHODS
  Multicenter clinical trial. Asthenopia patients were chosen from eleven hospitals cross China from July, 2008 to January, 2009. The experiment was conducted asthenopia patients who used the Esculin and Digitalis glycosides Eye Drops for 4 weeks continuously. Symptoms of asthenopia, UCVA (uncorrected vision acuity), refraction, amplitude of accommodation, accommodative lag, accommodative sensitivity and positive/negative relative accommodation were measured at different time points, such as treated before, 1 week and 4 week in treated after.
  
  
  RESULTS
  After the 4-week's use of Esculin and Digitalis glycosides Eye Drops, each subjective symptom of the patients was decreased significantly (F=353.30, P<0.05). In addition, most of the objective exams of accommodation ability were significantly improved, such as UCVA (left eye: F=23.39, P<0.05; right eye: F=15.62, P<0.05), refraction (left eye: F=10.34, P<0.05; right eye: F=17.13, P<0.05), amplitude of accommodation (left eye: F=14.46, P<0.05; right eye: F=8.29, P<0.05; eyes: F=13.86, P<0.05), accommodative lag (F=14.89, P<0.05) and accommodative sensitivity (left eye: F=62.67, P<0.05; right eye: F=68.77, P<0.05; eyes: F=82.74, P<0.05). And no patient appeared any adverse reaction in whole experiment.
  
  
  CONCLUSIONS
  Esculin and Digitalis glycosides Eye Drops is effective and safety for use in the patients of ametropia asthenopia.
authors.affiliation: Department of Ophthalmology, Eye Ear Nose & Throat Hospital, Fudan University, Shanghai 200031, China.
authors.forename: Zhen-ying
authors.initials: ZY
authors.lastname: Jiang
authors.forename: Xiao-mei
authors.initials: XM
authors.lastname: Qu
authors.forename: Xiao-xin
authors.initials: XX
authors.lastname: Li
authors.forename: Yu-ling
authors.initials: YL
authors.lastname: Liu
authors.forename: Nian-ci
authors.initials: NC
authors.lastname: Shen
authors.forename: Lin
authors.initials: L
authors.lastname: Zhang
authors.forename: Bi-lian
authors.initials: BL
authors.lastname: Ke
authors.forename: Pei-quan
authors.initials: PQ
authors.lastname: Zhao
authors.forename: Jun
authors.initials: J
authors.lastname: Jiang
authors.forename: Ke
authors.initials: K
authors.lastname: Yao
authors.forename: Jin
authors.initials: J
authors.lastname: Zeng
authors.forename: Xiao
authors.initials: X
authors.lastname: Yang
authors.forename: Ren-yuan
authors.initials: RY
authors.lastname: Chu
mesh_terms: D000328:Adult; D001248:Asthenopia / Q000188:drug therapy*; D004071:Digitalis Glycosides / Q000009:adverse effects / Q000627:therapeutic use*; D004929:Esculin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions / Q000009:adverse effects / Q000627:therapeutic use*; D008517:Phytotherapy; D012030:Refractive Errors / Q000188:drug therapy*; D014792:Visual Acuity; D055815:Young Adult
chemical_list: D004071:Digitalis Glycosides; D009883:Ophthalmic Solutions; D004929:Esculin